BRKR Bruker | $60.06 -0.9% | 7/7/2026 | | Boost Price Target | $60.00 ➝ $70.00 | Outperform | 00.00% | View details for Leerink Partners rating of Bruker (NASDAQ:BRKR) on 7/7/2026 |
AVTX Avalo Therapeutics | $19.21 -3.7% | 7/6/2026 | | Initiated Coverage | $38.00 | Outperform | 00.00% | View details for Leerink Partners rating of Avalo Therapeutics (NASDAQ:AVTX) on 7/6/2026 |
PBLS Parabilis Medicines | $30.57 +0.7% | 7/6/2026 | | Initiated Coverage | $40.00 | Outperform | 00.00% | View details for Leerink Partners rating of Parabilis Medicines (NASDAQ:PBLS) on 7/6/2026 |
PYXS Pyxis Oncology | $2.67 +1.1% | 7/2/2026 | | Lower Price Target | $9.00 ➝ $7.00 | Outperform | 00.00% | View details for Leerink Partners rating of Pyxis Oncology (NASDAQ:PYXS) on 7/2/2026 |
MLTX MoonLake Immunotherapeutics | $20.36 +2.2% | 7/1/2026 | | Boost Price Target | $24.00 ➝ $29.00 | Outperform | 00.00% | View details for Leerink Partners rating of MoonLake Immunotherapeutics (NASDAQ:MLTX) on 7/1/2026 |
ABVX Abivax | $139.90 -0.6% | 6/30/2026 | | Boost Price Target | $140.00 ➝ $148.00 | Outperform | 00.00% | View details for Leerink Partners rating of Abivax (NASDAQ:ABVX) on 6/30/2026 |
TECH Bio-Techne | $71.30 +0.2% | 6/25/2026 | | Set Price Target | $73.00 | | 00.00% | View details for Leerink Partners rating of Bio-Techne (NASDAQ:TECH) on 6/25/2026 |
LLY Eli Lilly and Company | $1,189.06 -2.3% | 6/25/2026 | | Boost Price Target | $1,119.00 ➝ $1,232.00 | Outperform | 00.00% | View details for Leerink Partners rating of Eli Lilly and Company (NYSE:LLY) on 6/25/2026 |
IONS Ionis Pharmaceuticals | $58.25 -9.4% | 6/25/2026 | | Boost Price Target | $122.00 ➝ $129.00 | Outperform | 00.00% | View details for Leerink Partners rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 6/25/2026 |
SPRY ARS Pharmaceuticals | $7.94 +0.8% | 6/25/2026 | | Lower Price Target | $25.00 ➝ $24.00 | Outperform | 00.00% | View details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 6/25/2026 |
Trump's gold order: the announcement they won't put on the front page (Ad) On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade.
Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction.
A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free. Request the free guide in 30 seconds and get positioned now |
TECH Bio-Techne | $71.30 +0.2% | 6/25/2026 | | Downgrade | | Strong-Buy ➝ Hold | 00.00% | View details for Leerink Partners rating of Bio-Techne (NASDAQ:TECH) on 6/25/2026 |
QNCX Quince Therapeutics | $17.54 +0.3% | 6/24/2026 | | Initiated Coverage | $80.00 | Outperform | 00.00% | View details for Leerink Partners rating of Quince Therapeutics (NASDAQ:QNCX) on 6/24/2026 |
RAPP Rapport Therapeutics | $41.75 -0.7% | 6/24/2026 | | Initiated Coverage | $52.00 | Outperform | 00.00% | View details for Leerink Partners rating of Rapport Therapeutics (NASDAQ:RAPP) on 6/24/2026 |
RGNX REGENXBIO | $13.95 -10.9% | 6/22/2026 | | Boost Price Target | $17.00 ➝ $18.00 | Outperform | 00.00% | View details for Leerink Partners rating of REGENXBIO (NASDAQ:RGNX) on 6/22/2026 |
DFTX Definium Therapeutics | $47.07 -2.8% | 6/22/2026 | | Set Price Target | $30.00 ➝ $52.00 | Outperform | 00.00% | View details for Leerink Partners rating of Definium Therapeutics (NASDAQ:DFTX) on 6/22/2026 |
ALT Altimmune | $3.05 -2.2% | 6/22/2026 | | Initiated Coverage | $10.00 | Outperform | 00.00% | View details for Leerink Partners rating of Altimmune (NASDAQ:ALT) on 6/22/2026 |
QURE uniQure | $42.63 -4.2% | 6/18/2026 | | Boost Price Target | $36.00 ➝ $70.00 | Outperform | 00.00% | View details for Leerink Partners rating of uniQure (NASDAQ:QURE) on 6/18/2026 |
ARWR Arrowhead Pharmaceuticals | $76.40 -9.0% | 6/17/2026 | | Boost Price Target | $61.00 ➝ $72.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 6/17/2026 |
IONS Ionis Pharmaceuticals | $58.25 -9.4% | 6/17/2026 | | Boost Price Target | $114.00 ➝ $122.00 | Outperform | 00.00% | View details for Leerink Partners rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 6/17/2026 |
UNH UnitedHealth Group | $425.05 -1.5% | 6/17/2026 | | Boost Price Target | $400.00 ➝ $462.00 | Outperform | 00.00% | View details for Leerink Partners rating of UnitedHealth Group (NYSE:UNH) on 6/17/2026 |
EWTX Edgewise Therapeutics | $45.41 -6.1% | 6/16/2026 | | Set Price Target | $52.00 | | 00.00% | View details for Leerink Partners rating of Edgewise Therapeutics (NASDAQ:EWTX) on 6/16/2026 |
SABS SAB Biotherapeutics | $3.82 -3.5% | 6/15/2026 | | Boost Price Target | $7.00 ➝ $12.00 | Outperform | 00.00% | View details for Leerink Partners rating of SAB Biotherapeutics (NASDAQ:SABS) on 6/15/2026 |
PRCT PROCEPT BioRobotics | $20.89 +5.8% | 6/11/2026 | | Downgrade | $31.00 ➝ $29.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of PROCEPT BioRobotics (NASDAQ:PRCT) on 6/11/2026 |
TNGX Tango Therapeutics | $31.06 +1.8% | 6/8/2026 | | Boost Price Target | $55.00 ➝ $69.00 | Outperform | 00.00% | View details for Leerink Partners rating of Tango Therapeutics (NASDAQ:TNGX) on 6/8/2026 |
SYK Stryker | $329.86 +0.8% | 6/5/2026 | | Lower Price Target | $410.00 ➝ $407.00 | Outperform | 00.00% | View details for Leerink Partners rating of Stryker (NYSE:SYK) on 6/5/2026 |
NBTX Nanobiotix | $40.07 +2.9% | 6/4/2026 | | Boost Price Target | $37.00 ➝ $46.00 | Outperform | 00.00% | View details for Leerink Partners rating of Nanobiotix (NASDAQ:NBTX) on 6/4/2026 |
ABSI Absci | $10.60 -7.6% | 6/4/2026 | | Initiated Coverage | $12.00 | Outperform | 00.00% | View details for Leerink Partners rating of Absci (NASDAQ:ABSI) on 6/4/2026 |
MDT Medtronic | $83.78 +1.7% | 6/4/2026 | | Lower Price Target | $117.00 ➝ $104.00 | Outperform | 00.00% | View details for Leerink Partners rating of Medtronic (NYSE:MDT) on 6/4/2026 |
NUVL Nuvalent | $123.90 +0.1% | 6/3/2026 | | Set Price Target | $165.00 | | 00.00% | View details for Leerink Partners rating of Nuvalent (NASDAQ:NUVL) on 6/3/2026 |
VIR Vir Biotechnology | $9.96 -3.7% | 6/3/2026 | | Boost Price Target | $20.00 ➝ $21.00 | Outperform | 00.00% | View details for Leerink Partners rating of Vir Biotechnology (NASDAQ:VIR) on 6/3/2026 |
CELC Celcuity | $107.58 -5.2% | 6/2/2026 | | Set Price Target | $155.00 | | 00.00% | View details for Leerink Partners rating of Celcuity (NASDAQ:CELC) on 6/2/2026 |
FULC Fulcrum Therapeutics | $3.50 -2.5% | 6/2/2026 | | Downgrade | $4.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Fulcrum Therapeutics (NASDAQ:FULC) on 6/2/2026 |
XFOR X4 Pharmaceuticals | $4.41 +11.4% | 6/2/2026 | | Initiated Coverage | $12.00 | Outperform | 00.00% | View details for Leerink Partners rating of X4 Pharmaceuticals (NASDAQ:XFOR) on 6/2/2026 |
ICLR Icon | $167.72 -0.6% | 5/28/2026 | | Set Price Target | $145.00 | | 00.00% | View details for Leerink Partners rating of Icon (NASDAQ:ICLR) on 5/28/2026 |
BSX Boston Scientific | $44.67 -0.7% | 5/28/2026 | | Lower Price Target | $87.00 ➝ $74.00 | Outperform | 00.00% | View details for Leerink Partners rating of Boston Scientific (NYSE:BSX) on 5/28/2026 |
EQ Equillium | $2.91 -1.7% | 5/28/2026 | | Upgrade | $1.00 ➝ $6.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Equillium (NASDAQ:EQ) on 5/28/2026 |
LLY Eli Lilly and Company | $1,189.06 -2.3% | 5/26/2026 | | Set Price Target | $1,119.00 | | 00.00% | View details for Leerink Partners rating of Eli Lilly and Company (NYSE:LLY) on 5/26/2026 |
SPTX Seaport Therapeutics | $21.58 +5.2% | 5/26/2026 | | Initiated Coverage | $35.00 | Outperform | 00.00% | View details for Leerink Partners rating of Seaport Therapeutics (NASDAQ:SPTX) on 5/26/2026 |
TWST Twist Bioscience | $90.64 -3.2% | 5/22/2026 | | Set Price Target | $80.00 | | 00.00% | View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 5/22/2026 |
EHC Encompass Health | $109.70 -1.2% | 5/22/2026 | | Set Price Target | $152.00 | | 00.00% | View details for Leerink Partners rating of Encompass Health (NYSE:EHC) on 5/22/2026 |
The $15 Gold Fund That Pays Up to $1,152/Month (Ad) Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. Discover the gold income fund before the next payout date |
ROIV Roivant Sciences | $35.97 -2.3% | 5/21/2026 | | Set Price Target | $42.00 | | 00.00% | View details for Leerink Partners rating of Roivant Sciences (NASDAQ:ROIV) on 5/21/2026 |
CGEN Compugen | $2.39 -3.2% | 5/21/2026 | | Lower Price Target | $13.00 ➝ $5.00 | Outperform | 00.00% | View details for Leerink Partners rating of Compugen (NASDAQ:CGEN) on 5/21/2026 |
IRD Opus Genetics | $3.92 -2.5% | 5/21/2026 | | Initiated Coverage | $10.00 | Outperform | 00.00% | View details for Leerink Partners rating of Opus Genetics (NASDAQ:IRD) on 5/21/2026 |
REGN Regeneron Pharmaceuticals | $664.52 -0.5% | 5/18/2026 | | Reiterated Rating | $792.00 ➝ $641.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 5/18/2026 |
ONC BeOne Medicines | $298.70 -1.4% | 5/15/2026 | | Boost Price Target | $364.00 ➝ $367.00 | Outperform | 00.00% | View details for Leerink Partners rating of BeOne Medicines (NASDAQ:ONC) on 5/15/2026 |
ANAB AnaptysBio | $66.39 -0.3% | 5/15/2026 | | Set Price Target | $90.00 | | 00.00% | View details for Leerink Partners rating of AnaptysBio (NASDAQ:ANAB) on 5/15/2026 |
IMNM Immunome | $23.35 -3.4% | 5/15/2026 | | Lower Price Target | $37.00 ➝ $33.00 | Outperform | 00.00% | View details for Leerink Partners rating of Immunome (NASDAQ:IMNM) on 5/15/2026 |
STRO Sutro Biopharma | $29.73 -0.9% | 5/15/2026 | | Set Price Target | $38.00 ➝ $43.00 | Outperform | 00.00% | View details for Leerink Partners rating of Sutro Biopharma (NASDAQ:STRO) on 5/15/2026 |
RNA Avidity Biosciences | $12.46 -3.5% | 5/15/2026 | | Initiated Coverage | | Outperform | 00.00% | View details for Leerink Partners rating of Avidity Biosciences (NASDAQ:RNA) on 5/15/2026 |
DOCS Doximity | $21.77 -1.1% | 5/14/2026 | | Lower Price Target | $31.00 ➝ $25.00 | Outperform | 00.00% | View details for Leerink Partners rating of Doximity (NYSE:DOCS) on 5/14/2026 |
AIRS AirSculpt Technologies | $4.33
| 5/14/2026 | | Set Price Target | $4.50 | | 00.00% | View details for Leerink Partners rating of AirSculpt Technologies (NASDAQ:AIRS) on 5/14/2026 |
ANTX Anthem | $4.50 -2.8% | 5/14/2026 | | Upgrade | $9.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Anthem (NASDAQ:ANTX) on 5/14/2026 |
TNGX Tango Therapeutics | $31.06 +1.8% | 5/14/2026 | | Boost Price Target | $28.00 ➝ $55.00 | Outperform | 00.00% | View details for Leerink Partners rating of Tango Therapeutics (NASDAQ:TNGX) on 5/14/2026 |
JNJ Johnson & Johnson | $257.17 -0.7% | 5/13/2026 | | Upgrade | $265.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Johnson & Johnson (NYSE:JNJ) on 5/13/2026 |
AURA Aura Biosciences | $6.84 -2.3% | 5/12/2026 | | Set Price Target | $17.00 | | 00.00% | View details for Leerink Partners rating of Aura Biosciences (NASDAQ:AURA) on 5/12/2026 |
ALMR Alamar Biosciences | $28.42 +7.3% | 5/12/2026 | | Initiated Coverage | $35.00 | Outperform | 00.00% | View details for Leerink Partners rating of Alamar Biosciences (NASDAQ:ALMR) on 5/12/2026 |
KLRA Kailera Therapeutics | $20.68 -1.6% | 5/12/2026 | | Initiated Coverage | $36.00 | Outperform | 00.00% | View details for Leerink Partners rating of Kailera Therapeutics (NASDAQ:KLRA) on 5/12/2026 |
ENGN enGene | $1.90 -1.0% | 5/8/2026 | | Downgrade | $2.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of enGene (NASDAQ:ENGN) on 5/8/2026 |
GILD Gilead Sciences | $129.83 -3.7% | 5/8/2026 | | Lower Price Target | $148.00 ➝ $146.00 | | 00.00% | View details for Leerink Partners rating of Gilead Sciences (NASDAQ:GILD) on 5/8/2026 |
PODD Insulet | $161.28 +1.9% | 5/7/2026 | | Lower Price Target | $360.00 ➝ $247.00 | | 00.00% | View details for Leerink Partners rating of Insulet (NASDAQ:PODD) on 5/7/2026 |
TWST Twist Bioscience | $90.64 -3.2% | 5/5/2026 | | Upgrade | $70.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 5/5/2026 |
ICLR Icon | $167.72 -0.6% | 5/4/2026 | | Set Price Target | $125.00 | | 00.00% | View details for Leerink Partners rating of Icon (NASDAQ:ICLR) on 5/4/2026 |
ORKA Oruka Therapeutics | $86.79 -1.7% | 4/30/2026 | | Set Price Target | $120.00 | | 00.00% | View details for Leerink Partners rating of Oruka Therapeutics (NASDAQ:ORKA) on 4/30/2026 |
ALGN Align Technology | $179.45 +0.7% | 4/30/2026 | | Boost Price Target | $225.00 ➝ $230.00 | | 00.00% | View details for Leerink Partners rating of Align Technology (NASDAQ:ALGN) on 4/30/2026 |
HUM Humana | $392.76 -1.3% | 4/30/2026 | | Boost Price Target | $185.00 ➝ $255.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Humana (NYSE:HUM) on 4/30/2026 |
KALV KalVista Pharmaceuticals | $27.00
| 4/29/2026 | | Downgrade | | Strong-Buy ➝ Hold | 00.00% | View details for Leerink Partners rating of KalVista Pharmaceuticals (NASDAQ:KALV) on 4/29/2026 |
NEO NeoGenomics | $14.11 -4.2% | 4/29/2026 | | Upgrade | $12.00 ➝ $25.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of NeoGenomics (NASDAQ:NEO) on 4/29/2026 |
ANAB AnaptysBio | $66.39 -0.3% | 4/28/2026 | | Boost Price Target | $66.00 ➝ $85.00 | Outperform | 00.00% | View details for Leerink Partners rating of AnaptysBio (NASDAQ:ANAB) on 4/28/2026 |
CRMD CorMedix | $8.40 -3.1% | 4/28/2026 | | Boost Price Target | $13.00 ➝ $14.00 | Outperform | 00.00% | View details for Leerink Partners rating of CorMedix (NASDAQ:CRMD) on 4/28/2026 |
NTLA Intellia Therapeutics | $14.22 -7.9% | 4/27/2026 | | Set Price Target | $35.00 | | 00.00% | View details for Leerink Partners rating of Intellia Therapeutics (NASDAQ:NTLA) on 4/27/2026 |
HCA HCA Healthcare | $406.45 -0.6% | 4/27/2026 | | Lower Price Target | $573.00 ➝ $500.00 | Outperform | 00.00% | View details for Leerink Partners rating of HCA Healthcare (NYSE:HCA) on 4/27/2026 |
LLY Eli Lilly and Company | $1,189.06 -2.3% | 4/27/2026 | | Lower Price Target | $1,296.00 ➝ $1,058.00 | Outperform | 00.00% | View details for Leerink Partners rating of Eli Lilly and Company (NYSE:LLY) on 4/27/2026 |
TRAX First Tracks Biotherapeutics | $36.24 +11.9% | 4/24/2026 | | Initiated Coverage | $46.00 | Outperform | 00.00% | View details for Leerink Partners rating of First Tracks Biotherapeutics (NASDAQ:TRAX) on 4/24/2026 |
ELV Elevance Health | $416.54 -0.9% | 4/23/2026 | | Set Price Target | $364.00 | | 00.00% | View details for Leerink Partners rating of Elevance Health (NYSE:ELV) on 4/23/2026 |
BBNX Beta Bionics | $17.03 +3.7% | 4/22/2026 | | Lower Price Target | $25.00 ➝ $24.00 | Outperform | 00.00% | View details for Leerink Partners rating of Beta Bionics (NASDAQ:BBNX) on 4/22/2026 |
DFTX Definium Therapeutics | $47.07 -2.8% | 4/22/2026 | | Boost Price Target | $23.00 ➝ $30.00 | Outperform | 00.00% | View details for Leerink Partners rating of Definium Therapeutics (NASDAQ:DFTX) on 4/22/2026 |
DNLI Denali Therapeutics | $25.68 -5.6% | 4/22/2026 | | Lower Price Target | $40.00 ➝ $35.00 | Outperform | 00.00% | View details for Leerink Partners rating of Denali Therapeutics (NASDAQ:DNLI) on 4/22/2026 |
ISRG Intuitive Surgical | $406.78 -1.2% | 4/22/2026 | | Lower Price Target | $622.00 ➝ $573.00 | Outperform | 00.00% | View details for Leerink Partners rating of Intuitive Surgical (NASDAQ:ISRG) on 4/22/2026 |
JAZZ Jazz Pharmaceuticals | $243.82 -1.3% | 4/22/2026 | | Boost Price Target | $215.00 ➝ $225.00 | Outperform | 00.00% | View details for Leerink Partners rating of Jazz Pharmaceuticals (NASDAQ:JAZZ) on 4/22/2026 |
MANE Veradermics | $119.72 -4.2% | 4/22/2026 | | Boost Price Target | $75.00 ➝ $90.00 | Outperform | 00.00% | View details for Leerink Partners rating of Veradermics (NYSE:MANE) on 4/22/2026 |
NBIX Neurocrine Biosciences | $177.11 -1.9% | 4/22/2026 | | Boost Price Target | $160.00 ➝ $170.00 | Outperform | 00.00% | View details for Leerink Partners rating of Neurocrine Biosciences (NASDAQ:NBIX) on 4/22/2026 |
UNH UnitedHealth Group | $425.05 -1.5% | 4/22/2026 | | Boost Price Target | $345.00 ➝ $400.00 | Outperform | 00.00% | View details for Leerink Partners rating of UnitedHealth Group (NYSE:UNH) on 4/22/2026 |
ABT Abbott Laboratories | $93.98 -0.5% | 4/21/2026 | | Lower Price Target | $119.00 ➝ $106.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Abbott Laboratories (NYSE:ABT) on 4/21/2026 |
RCUS Arcus Biosciences | $28.96 -3.4% | 4/20/2026 | | Set Price Target | $47.00 | | 00.00% | View details for Leerink Partners rating of Arcus Biosciences (NYSE:RCUS) on 4/20/2026 |
SNSE Sensei Biotherapeutics | $14.15 +2.1% | 4/20/2026 | | Initiated Coverage | $50.00 | Outperform | 00.00% | View details for Leerink Partners rating of Sensei Biotherapeutics (NASDAQ:SNSE) on 4/20/2026 |
JNJ Johnson & Johnson | $257.17 -0.7% | 4/15/2026 | | Boost Price Target | $232.00 ➝ $252.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Johnson & Johnson (NYSE:JNJ) on 4/15/2026 |
REPL Replimune Group | $10.99 -1.1% | 4/13/2026 | | Reiterated Rating | $11.00 ➝ $2.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Replimune Group (NASDAQ:REPL) on 4/13/2026 |
SYK Stryker | $329.86 +0.8% | 4/13/2026 | | Initiated Coverage | $410.00 | Outperform | 00.00% | View details for Leerink Partners rating of Stryker (NYSE:SYK) on 4/13/2026 |
SYRE Spyre Therapeutics | $97.74 -1.0% | 4/13/2026 | | Boost Price Target | $49.00 ➝ $106.00 | Outperform | 00.00% | View details for Leerink Partners rating of Spyre Therapeutics (NASDAQ:SYRE) on 4/13/2026 |
ZBH Zimmer Biomet | $91.52 +2.6% | 4/13/2026 | | Initiated Coverage | $101.00 | Hold | 00.00% | View details for Leerink Partners rating of Zimmer Biomet (NYSE:ZBH) on 4/13/2026 |
Your $29.97 book is free today (Ad) Why Some Traders Skip Stocks Entirely
You don't need a big account to trade options.
In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up.
This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account. Normally $29.97. Today it's free. Grab your copy now. |
STRO Sutro Biopharma | $29.73 -0.9% | 4/7/2026 | | Initiated Coverage | $38.00 | Outperform | 00.00% | View details for Leerink Partners rating of Sutro Biopharma (NASDAQ:STRO) on 4/7/2026 |
MSLE Satellos Bioscience | $9.79 +3.7% | 4/6/2026 | | Initiated Coverage | $20.00 | Outperform | 00.00% | View details for Leerink Partners rating of Satellos Bioscience (NASDAQ:MSLE) on 4/6/2026 |
CAMP CAMP4 Therapeutics | $4.33 -0.2% | 4/2/2026 | | Boost Price Target | $8.00 ➝ $9.00 | Outperform | 00.00% | View details for Leerink Partners rating of CAMP4 Therapeutics (NASDAQ:CAMP) on 4/2/2026 |
CNTA Centessa Pharmaceuticals | $40.50
| 4/1/2026 | | Downgrade | $36.00 ➝ $40.00 | Outperform ➝ Hold | 00.00% | View details for Leerink Partners rating of Centessa Pharmaceuticals (NASDAQ:CNTA) on 4/1/2026 |
INSM Insmed | $115.61 -2.2% | 3/24/2026 | | Boost Price Target | $210.00 ➝ $215.00 | Outperform | 00.00% | View details for Leerink Partners rating of Insmed (NASDAQ:INSM) on 3/24/2026 |
ANL Adlai Nortye | $9.87 -7.6% | 3/20/2026 | | Initiated Coverage | $23.00 | Outperform | 00.00% | View details for Leerink Partners rating of Adlai Nortye (NASDAQ:ANL) on 3/20/2026 |
PTGX Protagonist Therapeutics | $131.42 -4.5% | 3/19/2026 | | Boost Price Target | $107.00 ➝ $110.00 | Outperform | 00.00% | View details for Leerink Partners rating of Protagonist Therapeutics (NASDAQ:PTGX) on 3/19/2026 |
BTSG BrightSpring Health Services | $71.43 -0.2% | 3/18/2026 | | Reiterated Rating | $49.00 | Outperform | 00.00% | View details for Leerink Partners rating of BrightSpring Health Services (NASDAQ:BTSG) on 3/18/2026 |
COR Cencora | $303.31 +0.3% | 3/17/2026 | | Reiterated Rating | | Outperform | 00.00% | View details for Leerink Partners rating of Cencora (NYSE:COR) on 3/17/2026 |
GPCR Structure Therapeutics | $53.36 -3.2% | 3/16/2026 | | Reiterated Rating | | Outperform | 00.00% | View details for Leerink Partners rating of Structure Therapeutics (NASDAQ:GPCR) on 3/16/2026 |